ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 16, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 16, 2010
News
J&J Voluntarily Recalls Rolaids Products
By Patricia Van Arnum
McNeil Consumer Healthcare, a division of McNEIL-PPC, part of Johnson & Johnson (J&J, New Brunswick, NJ) issued a voluntary recall on Dec. 9, 2010, for Rolaid products in the United States and Canada due to reports of possible product contamination.
A Bad Year for Pharmaceutical R&D
By Stephanie Sutton
Figures released by the European Medicines Agency regarding the evaluation of marketing authorization (MA) applications show a significant decline in the number of approved products for 2010.
Abbott, B. Braun, and Roxane Pay $421.2 Million to Settle False-Claims Allegations
By Erik Greb
Abbott Laboratories (Abbott Park, IL), B. Braun Medical (Bethlehem, PA), and Roxane Laboratories, a subsidiary of Boehringer Ingelheim (Ingelheim am Rhein, Germany), agreed to pay the United States $421 million to settle False Claims Act allegations.
Pfizer's Thelin Withdrawn Due to Fatalities
By Stephanie Sutton
Following two cases of fatal liver injury, Pfizer has voluntarily withdrawn Thelin from the worldwide market and discontinued all ongoing trials.
Week of Dec. 13, 2010: Company and People Notes: Thermo Fisher to Acquire Dionex; Former SOCMA CEO Joe Acker Dies; and More.
Thermo Fisher to Acquire Dionex; Former SOCMA CEO Joe Acker Dies; and More.
Regulatory Roundup: FDA Issues Final Guidance on How to Comment on Advisory Committee Meetings
FDA Issues Final Guidance on How to Comment on Advisory Committee Meetings

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here